Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2022

SELL
$20.62 - $37.15 $1,175 - $2,117
-57 Closed
0 $0
Q1 2022

May 25, 2022

BUY
$23.5 - $35.38 $587 - $884
25 Added 78.13%
57 $2,000
Q4 2021

May 20, 2022

BUY
$29.21 - $44.64 $934 - $1,428
32 New
32 $1,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Fortitude Advisory Group L.L.C. Portfolio

Follow Fortitude Advisory Group L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortitude Advisory Group L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fortitude Advisory Group L.L.C. with notifications on news.